Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrip
Plus Updates On Mylan, Sinovac, Zydus Cadila
Scrip
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.
Scrip
Scrip’s eagerly awaited annual snapshot of pharma leadership in 2020 is here. The 2020 Titans of Pharma infographic features key information on the industry’s top leaders and the mega companies they oversee.
Topic Leadership Market Access
Scrip
CEO pay at the top 15 pharma companies increased by 3.9% in 2019. But how did that match up to company performance? Read the article now available from Scrip and learn who were the big winners, and how their companies performed financially.
Scrip
Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.
Topic Coronavirus Vaccines
Scrip
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.
Topic Coronavirus
Scrip
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
Scrip
Vaccines veteran calls Moderna ‘shabby’ for lack of transparency and shares sell-off, and flags CanSino’s own forthcoming Phase II results.
Scrip
CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.
Topic Coronavirus Vaccines
Scrip
Themis’ CEO on how Merck’s commitment to infectious diseases impressed him, and why regulators may not approve suboptimal COVID-19 vaccines.
Topic Coronavirus BioPharmaceutical
Scrip
The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?
Scrip
Sanofi’s €610m investment helps row to be forgotten – though Macron will ‘place bets’ on several COVID-19 vaccines, not just France’s homegrown candidate.
Topic Coronavirus Company Analysis
Scrip
The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.
Topic Coronavirus
Scrip
Novartis has accelerated its digital ambitions during the worldwide lockdown period, working with partners such as Doximity on engaging doctors and Science 37 on virtual trial tech.
Topic Coronavirus
Scrip
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.
Topic Coronavirus
Scrip
11 Jul 2020
Scrip
10 Jul 2020
Scrip
10 Jul 2020
Scrip
10 Jul 2020
Scrip
10 Jul 2020
Scrip
10 Jul 2020
Scrip
09 Jul 2020
Scrip
09 Jul 2020
Scrip
09 Jul 2020
Scrip
09 Jul 2020
Scrip
09 Jul 2020
Scrip
09 Jul 2020
Scrip
09 Jul 2020
Scrip
08 Jul 2020
Scrip
08 Jul 2020
New York, USA
Brenda specializes in
+39 year(s) experience
Washington DC, USA
Cathy specializes in
+39 year(s) experience
Washington DC, USA
Denise specializes in
+38 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date